Resistance training enhances glucose uptake in muscle cells through mechanisms independent of semaglutide

Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis

This week, the company launched a new platform called LillyDirect, which connects people with an independent telehealth company that prescribes obesity medications, as well as third-party services that can fill prescriptions and send them directly to a patients home
Keep a Food Journal Track what you eat and when sulfur burps occur
The short version: the combination appears safe for most patients, but your prescribing provider should know about both medications before you start either one